TABLE OF CONTENTS

Jul/Aug/Sep 2013; 2(3)

Progress of Immunotherapy for Hepatocellular Carcinoma

Hongbo Ma, Brian Wey, Liping Li

+Author Affiliations

Hongbo Ma

Department of Hepato-Biliary Pancreatic Surgery, Henan Tumor Hospital, the Affiliated Tumor Hospital of Zhengzhou University, China

Brian Wey

Public Health Research Institute, New Jersey Medical School, Rutgers Biomedical and Health Sciences, USA

Liping Li

Public Health Research Institute, New Jersey Medical School, Rutgers Biomedical and Health Sciences, USA

Corresponding Author:

Liping Li, ll549@njms.rutgers.edu

Abstract

Hepatocellular carcinoma (HCC) is one of the leading malignancies in developing countries, especially in China. The current treatment is valid for early stage disease but not effective for late stage and for preventing recurrence and metastasis. Immunotherapy has been considered as a promising therapy for the late stage of cancer for many years. In this review, we summarize current progress in immunotherapy for HCC . We put more weight on negative signals that produce immune suppression in tumor-bearing patients.

Received March 8, 2013.

Revised April 11, 2013.

Accepted April 17, 2013.

  • Previous
  • Next Article

Table of Contents

This Article

Published September 20, 2013;

DOI:10.7178/ig.48

Immunogastroenterology

2013;2(3): 167-172.

Abstract
Classifications
Review
Services
Email this article to a colleague
Alert me when this article is cited
Alert me if a correction is posted
Similar articles in this journal
Similar articles in PubMed
Download to citation manager
Google Scholar
PubMed
Social Bookmarking